Anthony Dayan worked as a pathologist before joining the pharmaceutical industry as a toxicologist and subsequently returning to head a university department of toxicology in London. He has been a member of official and industrial advisory committees on animal experimentation and the safety of medicines, foods and pesticides in the UK and internationally. He has been a consultant to many companies on drug and chemical safety programmes.
Kenneth Hastings was trained at the University of North Carolina at Chapel Hill and the Chemical Industry Institute of Toxicology. After Peace Corps service with the Ministry of Health, Republic of Fiji, he was a Research Associate in the Department of Anesthesiology, College of Medicine, University of Arizona. He then joined the US Food and Drug Administration, Center for Drug Evaluation and Research, Division of Anti-viral Drug Products, where he reviewed many of the early drugs for treatment of HIV/AIDS and related diseases. He served as supervisory toxicologist in the Division of Special Pathogen and Immunologic Drug Products, where he was part of review teams for tropical disease and transplant drugs. He concluded his career at FDA as an Associate Director in the Office of New Drugs. He represented the Agency on many regulatory initiatives, such as the International Conference on Harmonisation (ICH). After government service, he joined Sanofi-Aventis as Associate Vice-President for Regulatory Policy. He has served as President of the American College of Toxicology, the American Board of Toxicology, and the Immunotoxicology Specialty Section of the Society of Toxicology.
Peter McAnulty was trained at the University of London, and worked on various biochemical studies at the Institute of Child Health, part of London University. He then moved to Cambridge University and the Strangeways Research Laboratory, and began biochemistry and immunology research for the WHO. Dr. McAnulty began his CRO career at Life Science Research, where he became a toxicologist, and specialised in reproductive studies. When LSR became Pharmaco LSR, he became the Director of Pharmaceutcal Toxicology, and after that he was Principal Toxicologist at HLS. After that, Dr. McAnulty moved to Denmark and became the Scientific Director of Scantox. He has been a member of the Board of Directors of the American Board of Toxicology, and has been their President (2002-2003). He joined Ferring Pharmaceuticals in 2001, in the position of Executive Director, Nonclinical Development. In 2010 Dr. McAnulty became an Independent Nonclinical Consultant.
Niels-Christian Ganderup trained first in experimental biology and has had special experience of toxicology and ecotoxicology. Since 2005, he has been generally concerned with best use of the minipig in the biomedical sciences. His principal role has been active engagement world-wide with academic, pharmaceutical and other industrial research organisations and CROs in comparing the value of the minipig and other species in research and testing programmes in pharmacology and toxicology.
His broad interests cover the `Can I ...?', `How can I ...?' and `Who can show me how to ...?' questions. This has led him to facilitate cross-company and inter-organisation research consortia to extend scientific knowledge about the minipig and its uses in biomedical research. To further increase collaboration and to improve knowledge of techniques Niels-Christian Ganderup founded the Minipig Research Forum, a non-profit organisation, which organises annual scientific conferences in Europe and North America about all aspects of the use of minipigs in biomedical research. He is a regular speaker at conferences and is often consulted by universities, CROs and industrial groups about many aspects of the use of the minipig ranging from health and husbandry to training in experimental techniques and the development of new procedures.
More books by Peter A. McAnulty
More books by Anthony D. Dayan
More books by Niels-Christian Ganderup
More books by Kenneth L. Hastings